Earlier this month, the U.S. Food and
Drug Administration (FDA) approved a new epinephrine auto-injector,
Auvi-Q, for patients at risk for anaphylaxis. The
device provides audio and visual cues that lead patients or caregivers who are administering
an injection through the process, step-by-step. The hope is that this system
will improve care as surveys have shown that patients at risk of anaphylaxis do
not always know how to use their device during an emergency. Do you think this
will improve the quality-of-life of our patients with severe anaphylaxis?
I believe the benefit of a compact device like Auvi-Q will be for men and teenagers who are otherwise reluctant to carry autoinjectable epinephrine with them at all times. The size allows it to be easily carried. The convenience, more than the visual or audio cues, is the real selling-point of the device.
ReplyDeletethe U.S. Food and Drug Administration (FDA) approved a new epinephrine auto-injector, Auvi-Q, for patients at risk for anaphylaxis. Latest Technology News
ReplyDelete